A citation-based method for searching scientific literature

Philip Cohen, Darren Cross, Pasi A Jänne. Nat Rev Drug Discov 2021
Times Cited: 100







List of co-cited articles
664 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The protein kinase complement of the human genome.
G Manning, D B Whyte, R Martinez, T Hunter, S Sudarsanam. Science 2002
17

Trends in kinase drug discovery: targets, indications and inhibitor design.
Misty M Attwood, Doriano Fabbro, Aleksandr V Sokolov, Stefan Knapp, Helgi B Schiöth. Nat Rev Drug Discov 2021
71
22


Kinase inhibitors: the road ahead.
Fleur M Ferguson, Nathanael S Gray. Nat Rev Drug Discov 2018
425
11


Kinase-targeted cancer therapies: progress, challenges and future directions.
Khushwant S Bhullar, Naiara Orrego Lagarón, Eileen M McGowan, Indu Parmar, Amitabh Jha, Basil P Hubbard, H P Vasantha Rupasinghe. Mol Cancer 2018
411
11

A postmodern moral tale: the ethics of research relationships.
Margaret A Somerville. Nat Rev Drug Discov 2002
296
10

FDA-approved small-molecule kinase inhibitors.
Peng Wu, Thomas E Nielsen, Mads H Clausen. Trends Pharmacol Sci 2015
571
9

The target landscape of clinical kinase drugs.
Susan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm, Harald Polzer, Binje Vick, Paul-Albert Koenig, Maria Reinecke, Benjamin Ruprecht, Svenja Petzoldt, Chen Meng,[...]. Science 2017
380
7

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
7

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
6

Prospects for pharmacological targeting of pseudokinases.
Jennifer E Kung, Natalia Jura. Nat Rev Drug Discov 2019
53
11

New Promise and Opportunities for Allosteric Kinase Inhibitors.
Xiaoyun Lu, Jeff B Smaill, Ke Ding. Angew Chem Int Ed Engl 2020
43
13

Through the "gatekeeper door": exploiting the active kinase conformation.
Fabio Zuccotto, Elena Ardini, Elena Casale, Mauro Angiolini. J Med Chem 2010
324
6

PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials.
Fabrice Carles, Stéphane Bourg, Christophe Meyer, Pascal Bonnet. Molecules 2018
80
7

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, Silvia Buonamici, Simona Cotesta, Sandra W Cowan-Jacob, Stephanie Dodd, Peter Drueckes, Doriano Fabbro, Tobias Gabriel,[...]. J Med Chem 2018
132
6

NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
552
5


The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).
Fatima Ardito, Michele Giuliani, Donatella Perrone, Giuseppe Troiano, Lorenzo Lo Muzio. Int J Mol Med 2017
375
5

Ten things you should know about protein kinases: IUPHAR Review 14.
Doriano Fabbro, Sandra W Cowan-Jacob, Henrik Moebitz. Br J Pharmacol 2015
166
5

Allosteric Modulator Discovery: From Serendipity to Structure-Based Design.
Shaoyong Lu, Xinheng He, Duan Ni, Jian Zhang. J Med Chem 2019
84
5

Comprehensive analysis of kinase inhibitor selectivity.
Mindy I Davis, Jeremy P Hunt, Sanna Herrgard, Pietro Ciceri, Lisa M Wodicka, Gabriel Pallares, Michael Hocker, Daniel K Treiber, Patrick P Zarrinkar. Nat Biotechnol 2011
5


Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
Renaud Capdeville, Elisabeth Buchdunger, Juerg Zimmermann, Alex Matter. Nat Rev Drug Discov 2002
897
5

Induced protein degradation: an emerging drug discovery paradigm.
Ashton C Lai, Craig M Crews. Nat Rev Drug Discov 2017
583
5

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
5

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.
Federico Rossari, Filippo Minutolo, Enrico Orciuolo. J Hematol Oncol 2018
140
5

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
Cai-Hong Yun, Kristen E Mengwasser, Angela V Toms, Michele S Woo, Heidi Greulich, Kwok-Kin Wong, Matthew Meyerson, Michael J Eck. Proc Natl Acad Sci U S A 2008
5


KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space.
Oscar P J van Linden, Albert J Kooistra, Rob Leurs, Iwan J P de Esch, Chris de Graaf. J Med Chem 2014
165
5

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.
Jianming Zhang, Francisco J Adrián, Wolfgang Jahnke, Sandra W Cowan-Jacob, Allen G Li, Roxana E Iacob, Taebo Sim, John Powers, Christine Dierks, Fangxian Sun,[...]. Nature 2010
413
5

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
193
4

Larotrectinib: First Global Approval.
Lesley J Scott. Drugs 2019
85
4

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman,[...]. Lancet Oncol 2020
285
4

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, Nora Ku, Brian B Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R Kolakowski, Barbara J Brandhuber,[...]. Cancer Discov 2017
219
4

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy.
Charles Pottier, Margaux Fresnais, Marie Gilon, Guy Jérusalem, Rémi Longuespée, Nor Eddine Sounni. Cancers (Basel) 2020
122
4

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Lee A Honigberg, Ashley M Smith, Mint Sirisawad, Erik Verner, David Loury, Betty Chang, Shyr Li, Zhengying Pan, Douglas H Thamm, Richard A Miller,[...]. Proc Natl Acad Sci U S A 2010
4

The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis.
Uwe Knippschild, Marc Krüger, Julia Richter, Pengfei Xu, Balbina García-Reyes, Christian Peifer, Jakob Halekotte, Vasiliy Bakulev, Joachim Bischof. Front Oncol 2014
159
4

The Landscape of Atypical and Eukaryotic Protein Kinases.
Georgi K Kanev, Chris de Graaf, Iwan J P de Esch, Rob Leurs, Thomas Würdinger, Bart A Westerman, Albert J Kooistra. Trends Pharmacol Sci 2019
39
10

Dacomitinib: First Global Approval.
Matt Shirley. Drugs 2018
33
12

The (un)targeted cancer kinome.
Oleg Fedorov, Susanne Müller, Stefan Knapp. Nat Chem Biol 2010
197
4

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
Zhengying Pan, Heleen Scheerens, Shyr-Jiann Li, Brian E Schultz, Paul A Sprengeler, L Chuck Burrill, Rohan V Mendonca, Michael D Sweeney, Keana C K Scott, Paul G Grothaus,[...]. ChemMedChem 2007
424
4

The Dark Kinase Knowledgebase: an online compendium of knowledge and experimental results of understudied kinases.
Matthew E Berginski, Nienke Moret, Changchang Liu, Dennis Goldfarb, Peter K Sorger, Shawn M Gomez. Nucleic Acids Res 2021
24
16

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
Stephen T Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, James Kempson, John S Tokarski, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng,[...]. J Med Chem 2019
74
5

Comprehensive characterization of the Published Kinase Inhibitor Set.
Jonathan M Elkins, Vita Fedele, Marta Szklarz, Kamal R Abdul Azeez, Eidarus Salah, Jowita Mikolajczyk, Sergei Romanov, Nikolai Sepetov, Xi-Ping Huang, Bryan L Roth,[...]. Nat Biotechnol 2016
181
4

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Theonie Anastassiadis, Sean W Deacon, Karthik Devarajan, Haiching Ma, Jeffrey R Peterson. Nat Biotechnol 2011
590
4

Covalent-Allosteric Kinase Inhibitors.
Jörn Weisner, Rajesh Gontla, Leandi van der Westhuizen, Sebastian Oeck, Julia Ketzer, Petra Janning, André Richters, Thomas Mühlenberg, Zhizhou Fang, Abu Taher,[...]. Angew Chem Int Ed Engl 2015
61
6

The promise and peril of chemical probes.
Cheryl H Arrowsmith, James E Audia, Christopher Austin, Jonathan Baell, Jonathan Bennett, Julian Blagg, Chas Bountra, Paul E Brennan, Peter J Brown, Mark E Bunnage,[...]. Nat Chem Biol 2015
480
4


Emerging roles of pseudokinases.
Jérôme Boudeau, Diego Miranda-Saavedra, Geoffrey J Barton, Dario R Alessi. Trends Cell Biol 2006
389
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.